US2011263524A1PendingUtilityA1

Sns-595 and methods of using the same

57
Assignee: SUNESIS PHARMACEUTICALS INCPriority: Mar 15, 2004Filed: Apr 27, 2011Published: Oct 27, 2011
Est. expiryMar 15, 2024(expired)· nominal 20-yr term from priority
Inventors:Michelle ArkinJennifer HydeDuncan WalkerJasmin Wright
A61P 35/02A61P 43/00A61P 35/00A61P 7/06A61P 1/08A61P 13/08F24S 80/60F24S 10/70A61K 31/7048A61K 31/4375H02S 40/38A61K 38/1816Y02E10/52C07D 471/04A61K 31/585A61K 31/513A61K 45/06F24S 50/40A61K 38/15A61K 31/407A61K 31/7068A61K 31/44A61K 31/395A61K 31/337A61K 31/4745A61K 47/12A61K 31/52Y02E10/40A61K 31/555A61K 31/704A61K 31/519A61K 31/282A61K 41/00H10F 77/488H10F 77/63Y02E70/30H02S 40/44A61K 9/0019Y02E10/60Y02E10/44
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to SNS-595 and methods of treating cancer using the same.

Claims

exact text as granted — not AI-modified
1 - 37 . (canceled) 
     
     
         38 . A method for treating cancer comprising administering to a human patient having cancer a combination of: a) a therapeutically effective amount of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and b) a therapeutically effective amount of cytarabine. 
     
     
         39 . The method of  claim 38 , wherein the amount of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid administered to the patient is about 30 mg/m 2 -75 mg/m 2 . 
     
     
         40 . The method of  claim 38 , wherein the amount of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid administered to the patient is about 40 mg/m 2 -80 mg/m 2 . 
     
     
         41 . The method of  claim 38 , wherein the amount of (+)-1,4-dihydro-7-[(3S,45)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid administered to the patient is about 50 mg/m 2 -90 mg/m 2 . 
     
     
         42 . The method of  claim 38 , wherein the amount of cytarabine administered to the patient is at least 100 mg/m 2 . 
     
     
         43 . The method of  claim 38 , wherein the cancer is leukemia.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.